|Dr. Yuval Cohen||CEO & Director||837k||N/A||1975|
|Dr. Mark A. Tepper||Co-Founder & Consultant||565.5k||N/A||1957|
|Dr. Barbara White||Chief Medical Officer||593.6k||N/A||1950|
|Mr. Sean F. Moran CPA, M.B.A., CPA, MBA||Chief Financial Officer||N/A||N/A||1958|
|Ted Jenkins||Sr. Director of Investor Relations & Communications||N/A||N/A||N/A|
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restricted, CB1 inverse agonist, which is in a preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases. In addition, it has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Corbus Pharmaceuticals Holdings, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 4; Compensation: 9.